Compare ANNX & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | MLKN |
|---|---|---|
| Founded | 2011 | 1905 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Office Equipment/Supplies/Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 1.0B |
| IPO Year | 2020 | 1994 |
| Metric | ANNX | MLKN |
|---|---|---|
| Price | $5.36 | $16.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 565.0K |
| Earning Date | 05-11-2026 | 03-25-2026 |
| Dividend Yield | N/A | ★ 4.71% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.98 |
| Revenue | N/A | ★ $3,669,900,000.00 |
| Revenue This Year | N/A | $5.94 |
| Revenue Next Year | $16,320.74 | $3.78 |
| P/E Ratio | ★ N/A | $16.82 |
| Revenue Growth | N/A | ★ 1.14 |
| 52 Week Low | $1.85 | $13.77 |
| 52 Week High | $7.18 | $23.18 |
| Indicator | ANNX | MLKN |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 53.81 |
| Support Level | $4.80 | $13.87 |
| Resistance Level | $5.61 | $16.34 |
| Average True Range (ATR) | 0.28 | 0.57 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 55.96 | 86.96 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.